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praja2 regulates KSR1 stability andmitogenic signaling
L Rinaldi1,4, R Delle Donne1,4, M Sepe1, M Porpora1, C Garbi1, F Chiuso1, A Gallo1, S Parisi1, L Russo1, V Bachmann2,3, RG Huber2,3,
E Stefan2,3, T Russo1 and A Feliciello*,1
The kinase suppressor of Ras 1 (KSR1) has a fundamental role in mitogenic signaling by scaffolding components of the Ras/MAP
kinase pathway. In response to Ras activation, KSR1 assembles a tripartite kinase complex that optimally transfers signals
generated at the cell membrane to activate ERK. We describe a novel mechanism of ERK attenuation based on ubiquitin-dependent
proteolysis of KSR1. Stimulation of membrane receptors by hormones or growth factors induced KSR1 polyubiquitination, which
paralleled a decline of ERK1/2 signaling. We identified praja2 as the E3 ligase that ubiquitylates KSR1. We showed that praja2-
dependent regulation of KSR1 is involved in the growth of cancer cells and in the maintenance of undifferentiated pluripotent state
in mouse embryonic stem cells. The dynamic interplay between the ubiquitin system and the kinase scaffold of the Ras pathway
shapes the activation profile of the mitogenic cascade. By controlling KSR1 levels, praja2 directly affects compartmentalized ERK
activities, impacting on physiological events required for cell proliferation and maintenance of embryonic stem cell pluripotency.
Cell Death and Disease (2016) 7, e2230; doi:10.1038/cddis.2016.109; published online 19 May 2016
The Ras-Raf-ERK protein kinase cascade constitutes a
central signaling mechanism that controls important cell
functions, such as differentiation, metabolism and cell growth.
Activation of Ras by growth factors or G protein-coupled
receptor (GPCR) ligands promotes a kinase suppressor of
Ras 1 (KSR1)-mediated formation of a tripartite kinase
complex, which compartmentalizes Raf, MEK and ERK.1–3
By juxtaposing upstream and downstream signaling kinases,
KSR1 optimally couples stimulation of membrane receptors
to the propagation of the signals to a variety of ERK substrates
controlling multiple biological activities, such as cell proli-
feration, metabolism and synaptic activity.4–9 Dysregulation
or mutations in the genes encoding components of this
transduction pathway are frequently found in several human
cancers.10–12 Interfering with KSR1 function reduces Ras
signaling and cancer cell growth.13–17 Distinct attenuation
mechanisms of signaling cascade have been identified.18–20
As for mitogenic pathway, a negative loop between ERK1/2
and KSR1 ensures an efficient and tightly controlled cycle of
activation/de-activation process that limits unrestrained and
widespread activation of mitogenic signaling. Phosphorylation
of KSR1 and B-Raf by locally activated ERK1 dissociates the
KSR1multi-kinase complex, turning-off the ERK cascade.15,20
The mitogenic cascade could also be firmly regulated through
phosphorylation of Raf and KSR1 by cAMP-dependent protein
kinase (PKA).21 The bi-directional regulation of KSR1 and
ERK cascade, and the integration of the Ras pathway with
signals carried out by the GPCR•cAMP signaling axis control
the rate, magnitude and persistence of the downstream
mitogenic pathway.
The ubiquitin–proteasome system (UPS) emerged as an
important posttranslational mechanism that controls cell
growth, differentiation, metabolism and survival. The UPS
couples ubiquitylation of a target protein to its proteolytic
cleavage, eliminating unneeded or damaged proteins and
contributing to essential aspects of cell signaling and
homeostasis.22 The process involves the sequential action
of ubiquitin-activating enzymes (E1), ubiquitin-conjugating
enzymes (E2) and ubiquitin ligases (E3), where each enzyme
transfers ubiquitin molecules from one enzyme to the next and
eventually to the target protein. praja2 belongs to a growing
family of widely expressed mammalian RING-H2 proteins with
intrinsic E3 ubiquitin-ligase activity.23–26 During GPCR•cAMP
stimulation, praja2 ubiquitylates and degrades the inhibitory
(R) subunits of PKA, sustaining downstream signals carried
out by cAMP.27 In proliferating cells, praja2 promotes ubiquitin-
dependent proteolysis of MOB1, a core component the
tumor-suppressor Hippo cascade. Degradation of MOB1
through the UPS attenuates the Hippo cascade and sustains
tumor growth.28 A role of praja2•UPS in neuronal differen-
tiation and glucose homeostasis has also been recently
described.29,30 However, the impact of praja2 in the control
of ERK signaling was unknown.
Here we report that the KSR1 abundance is controlled by
specific components of the ubiquitin pathway. We identified
praja2 as the E3 ligase that ubiquitylates KSR1 in response to
growth factor or cAMP stimulation. Ubiquitination of KSR1
eventually attenuates the ERK1/2 cascade. By modulating
KSR1•ERK signaling, praja2 profoundly impacts on essential
aspects of embryonic stem cell (ESC) differentiation.
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Results
Identification of KSR1 as novel praja2 interactor. By
controlling the stability of protein kinases (PKA and Lats/
Mob1), praja2 integrates signals carried out by two evolu-
tionary conserved transduction cascades, having a major
role in cell proliferation and tumor growth.28 Large-scale
proteomic analyses revealed that praja2 is a component of
a macromolecular complex that includes the ERK scaffold
KSR1.31 Based on this finding, we tested whether praja2
interacts with and regulates the stability KSR1. First, we
demonstrated the interaction in vivo by isolating an endo-
genous praja2/KSR1 complex from cell lysates (Figure 1a).
Similarly, exogenous flag-praja2 and co-expressed myc-
KSR1 formed a stable complex in cell lysates (Figure 1b).
The core domain of praja2 (residues 401–530) was required
for KSR1 binding (Figure 1b). Next we confirmed a direct
interaction between KSR1 and praja2 in vitro. A fusion protein
carrying full-length praja2 fused to the C-terminus of
glutathione S-transferase polypeptide (GST) co-precipitated
in in vitro-translated, [35S]-labeled KSR1 (Figure 1c). To map
the praja2 interacting motif, overlapping 25-mer peptides
derived from human KSR1 sequence were spotted onto a
membrane and overlaid with purified GST-praja21–531
fusion protein, as previously described.32 We identified one
possible binding site for praja2 at the C-terminus of KSR1
with the core region DLQERPSFSL (Figure 1d). As expected,
a recombinant protein carrying the core peptide of KSR1
fused at the C-terminus of the GST polypeptide was sufficient
to bind praja2 in vitro (Figure 1e). The potential binding site is,
indeed, located at the surface of the predicted KSR1
structure, and thus it should be easily accessible for praja2
interaction (Figure 1f). In situ immunofluorescence analysis
revealed a partial co-localization between endogenous praja2
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Figure 1 praja2 interacts with KSR1. (a) Isolation of endogenous KSR1 and praja2 complex from lysates (2 mg) of HEK293 cells. (b) Schematic representation of the praja2
constructs used (upper diagram). HEK293 cells were transiently transfected with flag-praja2 (either wild-type, ring mutant (RM) or deletion mutants). Cells were treated for 12 h
with MG132 (10 μM) before harvesting. Twenty-four hours following transfection, cells were harvested and lysed. Lysates were subjected to immunoprecipitation with anti-KSR1
antibody. Precipitates were immunoblotted with anti-KSR1 and anti-flag antibodies (lower panels). (c) In vitro translated, [35S]-labeled KSR1 was subjected to pull-down assays
with purified GST or GST–praja2 fusion. (d) Spotted peptides (25 mers, 15mer overlap) of the human KSR1 sequence were overlaid with recombinant GST-praja2 (1–531)
followed by immunoblotting with anti-GST antibody. The sequences (in red) refer to the praja2-binding domain of KSR1. The amino acids methionine and cysteine have been
substituted with alanine or serine, respectively. (e) Schematic representation of the peptides used for pull-down experiments (upper panel). Lysates from flag-praja2-transfected
cells were subjected to pull-down experiment with GSTor GST-KSR1pep carrying the praja2-binding domain fused to GST (lower panels). (f) Predicted structure of KSR1 kinase
domain modeled on KSR2 template PDB 2Y4I. The position of the potential praja2-binding domain is indicated. (g) HEK293 cells were subjected to double immunostaining with
monoclonal anti-KSR1 and polyclonal anti-praja2 antibodies. Images were collected and analyzed by confocal microscopy. Pearson’s coefficients between praja2 and KSR1
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and KSR1. Overlapping signals could be detected at the
perinuclear region and within the cytoplasm (Figure 1g),
with a mean Pearson's coefficient of ~ 0.5. Altogether, these
data support the existence of a praja2/KSR1 complex in
living cells.
praja2 ubiquitylates KSR1. As praja2 is an E3 ubiquitin
ligase, we asked whether praja2 ubiquitylates KSR1. As
predicted, overexpression of praja2 induced accumulation of
polyubiquitinated forms of co-transfected KSR1 (Figure 2a).
In contrast, expression of a ligase inactive mutant of praja2
(praja2RM) reduced ubiquinated KSR1 levels below
the control value. Stimulation with epidermal growth factor
(EGF) induced a rapid and efficient accumulation of
polyubiquitinated KSR1 (Figure 2b). Stimulation by EGF of
KSR1 ubiquitination was prevented by praja2RM expression
(Figure 2c). Importantly, stimulation of β2-adrenergic receptor
with isoproterenol promoted KSR1 ubiquitination by praja2
(Figure 2d). PKA is a relevant effector of GPCR signaling.
Therefore, we tested whether general cAMP mobilization and
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Figure 2 praja2 ubiquitylates KSR1. (a) HEK293 cells were transfected with HA-ubiquitin and flag-praja2 or flag-praja2RM. Twenty-four hours after transfection, cells were
treated with MG132 (20 μM) for 8 h. Lysates were subjected to immunoprecipitations with anti-KSR1 and immunoblotted with anti-HA and anti-flag antibodies. (b) Cells were
transfected with HA-ubiquitin, serum-deprived overnight and stimulated with EGF (100 ng/ml) for the indicated time points. Lysates were subjected to immunoprecipitations
with anti-KSR1 and immunoblotted with anti-HA and anti-KSR1 antibodies. (c) Cells were transfected with HA-ubiquitin and flag-praja2 or flag-praja2RM and processed as in
panel (b). (d) HEK293 cells were transfected with HA-ubiquitin and control (siRNAc) or SMARTpool siRNApraja2. Twenty-four hours after transfection, cells were either left
untreated or stimulated with isoproterenol in the presence of MG132. Lysates were subjected to immunoprecipitations with anti-KSR1 and immunoblotted with anti-HA and anti-
KSR1 antibodies. (e) Same as in panel (d), with the exception that the cells were stimulated with Fsk (40 μM, 30 min). (f) In vitro-translated, 35S-labeled KSR1 was incubated with
anti-flag precipitates (flag-praja2 or flag-praja2RM) isolated from growing cells and his6-tagged ubiquitin, in the presence of E1 and UbcH5c (E2). The reaction mix was denatured,
size-fractionated on SDS-PAGE and analyzed by autoradiography. A fraction of the reaction mixture was immunoblotted with anti-flag antibody (lower panel)
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PKA activation per se contribute to KSR1 ubiquitination. As
shown in Figure 2e, treatment with the cAMP-elevating agent
Forskolin (Fsk) rapidly induced KSR1 polyubiquitination.
Genetic knockdown (KD) of praja2 prevented Fsk-induced
KSR1 ubiquitination. In vitro ubiquitination assays demon-
strated that praja2, but not its inactive mutant, directly
ubiquitylates KSR1 (Figure 2f).
These findings demonstrate that KSR1 is targeted by the
ubiquitin pathway in response to stimulation of receptor tyrosine
kinase (RTK) or GPCR. This implies that praja2 will reduce
KSR1 levels. We tested this hypothesis by measuring KSR1 in
cells expressing praja2 (either wild type or RING mutant). As
shown in Figures 3aand b, praja2 significantly lowered,whereas
praja2RM increased, the levels of endogenous KSR1, relative to
the control. Pretreating the cells with the proteasome inhibitor
MG132 partly restored KSR1 levels, even in the presence of
overexpressed praja2 (Supplementary Figure S1), supporting a
role of the proteasome in controlling KSR1 stability.
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Figure 3 praja2 decreases KSR1 levels. (a) Immunoblot of lysates from cells transiently transfected with Flag-praja2 vector (either wild type or RING mutant). (b) Quantitative
analysis (mean± S.E.M) of three independent experiments shown in panel (a) **Po0.01. (c) Cells were transfected with control (siRNAc) or SMARTpool siRNApraja2. Twenty-
four hours after transfection, cells were either left untreated or stimulated with Fsk (40 μM, 30 min). To prevent effects of Fsk on protein synthesis, cells were pretreated with
cycloheximide. (d) Quantitative analysis of three independent experiments shown in panel (e). *Po0.05 versus control (siRNAc), untreated cells. (e) Immunoblot of lysates from
cells transfected with flag-praja2 vector (either wild type or praja2S342A,T389A). Twenty-four hours after transfection, cells were either left untreated or stimulated with Fsk (40 μM)
and harvested at the indicated time points
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Our ubiquitination experiments suggest that elevated cAMP
levels elicited by GPCR activation or Fsk treatment induced
KSR1 ubiquitination by praja2. We therefore asked whether
cAMP accumulation was sufficient to reduce KSR1 levels. As
shown in Figures 3c and d, the levels of KSR1 decreased
following Fsk treatment. The effects of Fsk on KSR1 were
reversed by praja2 depletion (Figures 3c and d) or by
expressing a praja2mutant (Flag-praja2S342A,T389A) that cannot
be phosphorylated and activated by PKA (Figure 3e).27
praja2 attenuates KSR1-dependent ERK1/2 phosphoryla-
tion. The data above indicate that praja2 regulates the KSR1
stability. Given the role of KSR1 in ERK1/2 signaling, we
investigated whether praja2 modulates ERK activity. To this
end, we monitored ERK1/2 phosphorylation at its active site
(Thr202/Tyr204) in cells stimulated with EGF. As shown in
Figures 4a and b, we observed that EGF treatment induced
a time-dependent phosphorylation of ERK1/2. Expression
of praja2RM increased both basal and EGF-induced ERK
phosphorylation by several fold over control values. The high
levels of basal ERK phosphorylation in praja2RM-transfected
cells support the role of endogenous praja2 in attenuating
ERK activity in serum-deprived cells. The same experiments
were replicated in human osteosarcoma cells (U2OS)
(Supplementary Figure S2A). The effects of praja2RM on
ERK1/2 phosphorylation was inhibited by pretreating the cells
with the MEK inhibitor U0126 (Supplementary Figure S2B).
The interaction to KSR1 was required for praja2RM action.
Thus a praja2RM lacking the KSR-binding domain had no
effects on ERK1/2 phosphorylation profile (Figure 4c).
Similarly, genetic KD of endogenous praja2 also sustained
ERK1/2 phosphorylation, compared with controls (Figure 4d
and Supplementary Figure S3).
ERK phosphorylation in praja2 siRNA-transfected cells was
downregulated by concomitant KSR1 depletion (Figure 4e),
suggesting that KSR1 is a relevant target of praja2 in shaping
ERK signaling. Next we tested whether praja2 regulates ERK
phosphorylation in the course of GPCR stimulation.
cAMP accumulation within cells inhibits the ERK1/2
cascade by different mechanisms.33–35 The data above
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time points. (g) Quantitative analysis of the experiments shown in panel (e)
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indicate that cAMP promotes ubiquitination of KSR1 through
praja2. This suggested that cAMP may inhibit ERK phos-
phorylation by promoting KSR1 ubiquitination. We tested
this hypothesis by monitoring ERK phosphorylation in cells
exposed to EGF in the presence or absence of Fsk. Figures 4f
and g show that cAMP inhibits ERK phosphorylation induced
by EGF, as described previously.33–35 cAMP inhibition of ERK
signaling was abrogated by the praja2S342A,T389A mutant
(Figures 4f and g), supporting a key role of the ligase in
mediating cAMP effects on ERK cascade.
We next showed that binding to KSR1 was required for
praja2 inhibition of ERK1/2 signaling. Cells were pretreated for
6 h with a synthetic peptide spanning the praja2-binding motif
of KSR1 (go-onERK-Flag) or with a scrambled peptide
(scrambled-Flag). The peptides were linked to a stearate
group to facilitate the cellular uptake (Figure 5a, lower panel).
As shown in Supplementary Figure S4, both peptides
efficiently accumulated within the treated cells. As expected,
treatment with go-onERK-Flag decreased praja2 binding to
KSR1 (Figure 5a, upper panel and Figure 5b). The cells were
then stimulated with EGF and ERK1/2 phosphorylation was
monitored over a time-point curve. Pretreatment with go-
onERK-Flag enhanced both basal and EGF-induced ERK
phosphorylation compared with controls (Figures 5c and d).
The effects of KSR1go-onERK-flag on ERK phosphorylation
were replicated in other cell lines, including LNCAP and U-87
MG (Supplementary Figure S5).We alsomonitored the effects
of the peptide treatment on the growth of human cancer cells.
As shown in Figure 5e, KSR1go-onERK-flag inhibited the
growth of MCF-7 by about twofolds, compared with controls.
praja2 regulates ERKs in ESCs. In addition to mitogenic
signaling, ERKs are crucially involved in cell differentiation.
Stimulation of the ERK1/2 cascade by basic fibroblast growth
factor (bFGF) governs mouse ESC fate, regulating the
transition between naive pluripotency and epiblast-like state
committed to differentiation (epiblast-like stem cells
(EpiSCs)).36–39 We observed that both praja2 and KSR1
are expressed in both ESCs and EpiSCs (Figure 5f). The
levels of praja2 and KSR1 are inversely correlated during the
transition from ESCs to EpiSCs. The boost of ERK activation
soon after the transition induction is concomitant with the
decrease of praja2 and the accumulation of KSR1 (Figure 5g)
and is in agreement with the function of Erk1/2 in triggering
transition of pluripotent ESCs from ground to a primed
state.36 It is worth noting that P-ERK level declines soon after
the boost of activation, likely due to the activation of
phosphatase Dusp6,40 whereas KSR1 continues to accumu-
late. This suggests that KSR accumulation is also involved in
further functions, different from that leading to transient ERK
activation. Suppression of praja2 by RNAi in ESCs induced
the accumulation of KSR1 and was accompanied by a robust
phosphorylation of ERKs (Figure 5g), thus indicating that
downregulation of KSR1 by praja2 could contribute to
maintain appropriate levels of ERK phosphorylation in ESCs.
ERK1/2 phosphorylation was also observed in ESCs
exposed to the go-onERK-Flag peptide (Figure 5h) and was
comparable to that provoked by the treatment with bFGF.36
To explore the role of praja2 in ERK-dependent ESCs
differentiation, we exposed ESCs to go-onERK-Flag peptide
in a medium without LIF and serum and with activin, which
favors the exit from naive pluripotency.41 We first assessed
whether ERK1/2 induction by go-onERK-Flag peptide
activates the downstream pathways. It is well known that
ERK activation during the transition from ESCs to EpiSCs
downregulates the transcription of Tbx3, a known downstream
target of ERK signaling.39 As shown in Figure 5i, exposure of
ESCs to bFGF or to go-onERK-Flag peptide resulted in the
downregulation of Tbx3. Considering that Nanog gene is, in
part, under the control of Tbx3, we asked whether go-onERK-
Flag peptide affected Nanog gene expression. Figure 5i
shows that Nanog mRNA was decreased upon exposure of
the cells to go-onERK-Flag peptide. Therefore, the induction of
ERKs by go-onERK-Flag peptide appeared to have the
expected physiological downstream effect. However, go-
onERK-Flag treatment alone failed to induce the differentiation
of ESCs, thus confirming that, in addition to ERK activation,
other events, such as the induction of GSK3β, are necessary
to sustain ESC differentiation into EpiSCs.
Discussion
Here we report for the first time the identification of KSR1 as a
target of the UPS. We identified praja2 as the E3 ligase
responsible for KSR1 ubiquitination. We found that, in the
course of hormone stimulation by RTKs and GPCRs ligands,
KSR1 undergoes rapid polyubiquitination and proteolysis,
which eventually leads to attenuation of ERK-mediated signal
transmission.
Signal propagation originating at cell membranes is
efficiently transmitted to compartmentalized downstream
effectors. To ensure specificity, it is also necessary to restrict
signaling temporally by desensitizing the transmitter of the
input signal. The intricate interplay between ON and OFF
states of signaling pathways gives rise to signaling waves that
rapidly propagate throughout the cell, eliciting biological
responses that strictly depend on the intensity and frequency
of the oscillatory circuits. A variety of attenuation mechanisms
have been identified.18–20 In the case of the ERK pathway, a
negative loop between ERK and KSR1 ensures a cycle of
activation/de-activation process that limits uncontrolled mito-
genic signaling. Phosphorylation of KSR1 and B-Raf by locally
activated ERK1 dissociates the KSR1 multi-kinase complex,
turning-off the ERK cascade.15,20 Phosphorylation of Raf
and KSR1 by PKA also modulates ERK activity.21 The
bi-directional regulation of KSR1 and ERK cascade and the
integration of the Ras pathway with signals carried out by
cAMP ultimately control the rate, magnitude and persistence
of the downstream mitogenic pathway.
Previous findings indicated that KSR1 protein stability could
be regulated at the posttranslational level.8,42 However, the
mechanisms underlying the control of KSR1 stability were
unknown. Our work adds a novel twist in the ERK cascade,
identifying KSR1 as a target of the UPS. Ubiquitination of
KSR1 is rapidly induced by cAMP•PKA pathway. Ubiquiti-
nated KSR1 eventually undergoes proteolysis through
the proteasome. This parallels downregulation of the
ERK cascade. Interfering with praja2 expression/activity or
expressing a praja2 mutant carrying mutations within the
PKA phosphorylation sites negatively impacted on KSR1
praja2 ubiquitylates KSR1
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Figure 5 Interfering with praja2-KSR1 complex enhances ERK signaling in ES and cancer cells. (a) Cells were pretreated for 8 h with the following synthetic peptides (1 μM):
scrambled-Flag and KSR1pep-Flag, renamed as go-onERK-Flag, given its role in ERK signaling (see below). Lysates were immunoprecipitated for KSR1. The precipitates were
immunoblotted for praja2 and KSR1 (upper panel). Schematic representation of the scrambled and go-onERK peptides (lower panel). (b) Quantitative analysis of the experiments
shown in panel (a). The data represent a mean of two independent experiments. (c) Cells pretreated (7 h) with the synthetic peptides (1 μM) (scrambled-Flag and go-onERK-
Flag) were left untreated or stimulated with EGF. Lysates were immunoblotted for phosphoERK and ERK. (d) Quantitative analysis of the experiments shown in panel (c).
(e) MCF-7 cells were treated for 48 h with the scrambled-Flag peptide or with go-onERK-Flag peptide, harvested and counted. A mean of three independent
experiments± S.E.M. is shown. (f) E14Tg2a mouse ESCs were grown on feeder-free, gelatin-coated plates as described49 and were induced to differentiate into EpiSCs in
fibronectin-coated dishes at a density of 2.5 × 105cells/cm2 in the presence of 20 ng/ml Activin A and 12 ng/ml bFGF as described.50 Lysates from cells were immunoblotted with
the indicated antibodies. (g) Undifferentiated ESCs were transfected with control (siRNAc) or SMARTpool siRNApraja2. Lysates were immunoblotted with the indicated
antibodies. (h) Cells treated (1 and 7 h) with the synthetic peptides (scrambled-Flag and go-onERK-Flag-Flag) or with 12 ng/ml bFGF. Lysates were immunoblotted for the
indicated antibodies. (i) ESCs were grown in undifferentiated conditions in the presence of LIF and serum (ESCs) or in EpiSC medium (containing Activin) for 48 h with bFGF
(EpiSCs+bFGF) or without it (EpiSCs), in the presence of scrambled-Flag or go-onERK-Flag. Q-PCR analysis of Tbx3 and Nanog mRNAs, relative to GAPDHmRNA. The results
are expressed as mean± S.E.M of three independent experiments (*Po0.05)
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ubiquitination, enhancing ERK1/2 activation and prolonging
the wave of downstream signaling. Moreover, a peptide
targeting the praja2-binding interface on KSR1 increased both
basal and ligand-induced ERK1/2 phosphorylation, support-
ing the role of praja2 in negatively controlling the KSR1
signaling. praja2 acts also in response to EGF stimulation in
promoting KSR1 ubiquitination and ERK attenuation, pointing
to a more general role of praja2 in controlling the strength and
duration of KSR1-orchestrated ERK cascade. The biological
relevance of this mechanism was supported by the finding that
interfering with praja2/KSR1 interaction significantly affected
the growth rate of human cancer cells. In this context, inhibition
of tumor cells growth by the praja2/KSR1 displacing peptide
may provide a new therapeutic strategy to selectively interfere
with the growth and development of malignant lesions.
The functional relevance of KSR1 regulation by praja2 also
emerged in mouse ESCs. Tight control of ERK1/2 activation is
known to be crucial to maintain ESCs in the pluripotent ground
state and to drive differentiation of these cells into the epiblast-
like phenotype.36,39,43 The fundamental role of this control
is supported by the observation that the pluripotent ground
state can be sustained, in the absence of LIF and serum, by
inhibitors of ERKs and GSK3β.37 We show that praja2
regulates KSR1 abundance in ESCs and, in turn, supports
the ERK activation that is crucial for ESC differentiation.
This observation sheds new light of the molecular events
involved in the transition from preimplantation into post-
implantation phenotype of epiblast cells and suggests to
further explore the regulation of this machinery in the
maintenance of pluripotency, in the differentiation of ESC
and in the reprogramming.
In conclusion, our findings highlight the importance of
praja2•UPS in the control of growth factor signaling, pointing
to KSR1 as a relevant target of praja2. Identification of a core
motif within the KSR1 structure that mediates praja2 binding
provides a potential strategy to interfere selectively with
Ras•KSR1•ERK signaling in living cells. Exploring further
the mechanism(s) regulating ubiquitination of KSR1 in course
of hormone and growth factor stimulation and identifying
additional UPS targets in the ERK cascade will provide
essential tools to dissect and manipulate these important
signaling pathways in human diseases.
Materials and Methods
Cell lines. Human embryonic kidney cell line (HEK293), glioblastoma cells (U87-
MG) and osteosarcoma cells (U2OS) were cultured in Dulbecco's modified Eagle’s
medium containing 10% fetal bovine serum in an atmosphere of 5% CO2. To favor
EpiSC differentiation, 106 cells per 10 cm2 were plated on TC dishes pretreated with
Fibronectin (Sigma, Saint Louis, MO, USA) in the following medium: 1 volume of
DMEM/F12 combined with 1 volume of Neurobasal medium, supplemented with 0.5%
N2 supplement, 1% B27 supplement, 1% KO serum replacement, 2 mM glutamine
(Invitrogen, Carlsbad, MO, USA), 20 ng/ml Activin A (R&D Systems, Minneapolis, MN,
USA) with or without 12 ng/ml of bFGF (Preprotech). Within 2 days in these conditions,
the cells undergo morphological transformation (including flattening, diminished cell–cell
interactions and formation of cellular protrusions) and express epiblast markers.41
Plasmids and transfection. Vectors encoding for flag-praja2 (either wild
type or mutants) and GST-praja2 were purchased from (Genecopeia, Rockville, MD,
USA); HA-tagged ubiquitin was previously described;44 KSR1 vectors were kindly
provided by Dr. Richard Kolesnick and Dr. Andrey Shaw. SMART pool siRNAs
targeting distinct segments of coding regions of praja2 and KSR1 were purchased
from (Thermo Scientific, Waltham, MA, USA) and Sigma. siRNAs were transiently
transfected using Lipofectamine 2000 (Invitrogen) at a final concentration of
100 pmol/ml of culture medium. For siRNA experiments, similar data were obtained
using a mixture or four or two independent siRNAs. Transfection efficiency was
monitored by including a GFP vector in the transfection mixture.
Following are the siRNA sequences (Thermo Scientific; LU-006916-00-10)
targeting human praja2:
Sequence 1: 5′-GAAGCACCCUAAACCUUGA-3′;
Sequence 2: 5′-AGACUGCUCUGGCCCAUUU-3′;
Sequence 3: 5′-GCAGGAGGGUAUCAGACAA-3′; and
Sequence 4: 5′-GUUAGAUUCUGUACCAUUA-3′.
RNA isolation and quantitative real-time PCR (Q-PCR). Total RNA
was extracted by using TRISURE (Bioline, Taunton, MA, USA). The first-strand cDNA
was synthesized using the M-MLV RT Kit (New England BioLabs, Ipswich, MA, USA)
according to the manufacturer’s instructions. Q-PCR was carried out with the
QuantStudio 7 Flex Real-Time PCR System instrument and software (Applied
Biosystems, Carlsbad, CA, USA) using Power SYBR Green PCR Master mix (Applied
Biosystems). The housekeeping GAPDH mRNA was used as an internal standard for
normalization. Gene-specific primers used for amplification are listed below.
Tbx3:
5′-CGAAGTCAGGAAGGCGAATG-3′;
5′-TGTCCATCAATAAAATATACTTGGCC-3′
Gapdh:
5′-GTATGACTCCACTCACGGCAAA-3′
5′-TTCCCATTCTCGGCCTTG-3′
Nanog:
5′-TCAGAAGGGCTCAGCACCA-3′
5′-GCGTTCACCAGATAGCCCTG-3′
Antibodies and western blotting analysis. Cells were lysed in a buffer
containing 1 mM EDTA, 50 mM Tris-HCl (pH 7.5), 70 mM NaCl and 1% Triton. The
following primary antibodies were used: rabbit Praja2 (Bethyl Laboratories,
Montgomery, TX, USA), mouse GAPDH (Santa Cruz Biotechnology, Dallas, TX,
USA), rabbit KSR1 (Cell Signalling, Danvers, MA, USA), rabbit Phospho ERK
(Thr202/Tyr204) (Cell Signalling), rabbit ERK2 (Santa Cruz) and rabbit ERK1 (Santa
Cruz). Antibody protein complexes were detected by HRP-conjugated antibodies
and ECL (both from Amersham Pharmacia, Piscataway Township, NJ, USA).
Immunoprecipitation and pull-down assay. Cells were homogenized
and subjected to immunoprecipitation and immunoblot analyses as described
previously.29 GST-fusions were expressed and purified from BL21 (DE3) pLysS
cells. GST hybrid proteins (GST and GST-pep) immobilized on glutathione beads
were incubated for 3 h with cell lysates from HEK293 cells transiently expressing
flag-praja2. For in vitro-binding assays, 20 μl of GST and GST-praja2 beads were
incubated in in vitro-translated, [35S]-labeled KSR1 in 200 μl lysis buffer (150 mM
NaCl, 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5% triton X-100) in rotation at 4 °C
overnight. Pellets were washed four times in lysis buffer supplemented with NaCl
(0.4 M final concentration) and eluted in Laemmli buffer. Eluted samples were size-
fractionated on SDS-PAGE and immunoblotted or subjected to autoradiography.
In vitro ubiquitination assay. [35S]-labeled KSR1 was synthesized in vitro
using TnT quick coupled transcription/translation system (Promega, Fitchburg, WI,
USA) in the presence of 45 μCi of [35S]-labeled methionine. The ubiquitination
assay was performed as described previously.27
SPOT synthesis and overlay experiments. Overlapping peptides of
human KSR1 were SPOT-synthesized (synthetic peptide arrays on membrane
supports) on distinct coordinates of a cellulose membrane (starting from the
N-terminus of KSR1 with amino acid 1–25 (coordinate A1), amino acid 11–35
(coordinate A2), etc.). The amino acids methionine and cysteine have been
substituted with alanine or serine respectively. Membranes equilibrated in TBST buffer
(10 mM Tris, 150 mM NaCl, 0,05% Tween 20, pH 7,4) were overlaid with recombinant
GST-praja2 (1–531) (10 μg/ml blocking buffer (TBST supplemented with 5% non-fat
dry milk)). Interactions were detected with rabbit anti-GST and secondary horseradish
peroxidase antibodies by a procedure identical to immunoblotting.
Immunofluorescence and confocal analysis. For immunofluorescence
study, HEK293 cells were plated on poly-L-lysine coated (10 μg/ml) glass coverslips.
Cells were fixed and immunostained with ant-KSR1 (1 : 100) and anti-praja2
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(1 : 500) antibodies for the endogenous protein levels, with anti-Flag (1 : 500)
antibody for the peptides. Immunofluorescence was visualized using a Zeiss
LSM 510 Meta argon/krypton laser scanning confocal microscope (Oberkochen,
Germany). Quantification of the immunofluorescent images and correlation (Pearson’s)
coefficient were calculated by the Image-J software (NIH, Bethesda, MD, USA).
Homology modeling. The sequence of human KSR1 was retrieved from
Uniprot (KSR1_HUMAN, Q8IVT5) and aligned with the sequence of KSR2
(KSR2_HUMAN, Q6VAB6) using Clustal Omega at EMBL-EBI.45,46 The result of
this alignment is shown in Supplementary Figure S6. The structure of the kinase
domain of KSR2 has been determined by Brennan et al.47 (PDB 2Y4I). Residues
with known structure are indicated in yellow. Subsequently, a homology model
based on this structural template was created using MOE2013.08. Ten intermediate
models were generated and energy minimization was performed for each model
using the Amber force field ff99SB48 and implicit solvation. The lowest energy state
of the 10 models was subsequently chosen as the final model.
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